Skip to main content
Figure 7 | Gut Pathogens

Figure 7

From: Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis

Figure 7

Schematic model for the immunomodulatory effects of Lactococcus lactis NCDO 2118 in DSS-induced colitis. Orally administered Lactococcus lactis NCDO 2118 is able to induce an early increase in IL-6 production and to sustain IL-10 secretion in colonic tissue of the dextran sulphate sodium (DSS)-induced murine model of ulcerative colitis. It also increases the number of local tolerogenic dendritic cells (CD11c+CD11b-CD103+). These cells migrate to the mesenteric lymph nodes and stimulate the expansion of CD4+CD25+LAP+ cells, a regulatory type of T cell (Treg), leading ultimately to downmodulation of colitis.

Back to article page